<DOC>
	<DOCNO>NCT00614575</DOCNO>
	<brief_summary>The primary objective investigation conduct 12-week prospective survey PD patient depressive symptom treat BI Sifrol Tablets ( hereinafter refer drug ) routine clinical setting determine follow item relate safety efficacy . . Adverse drug reaction symptom , incidence , severity ii . Motor capacity investigation iii . Depressive symptom investigation</brief_summary>
	<brief_title>Survey PD Patients With Depressive Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : **PD patient depressive symptom Patients receive pramipexole hydrochloride hydrate preparation within 1 month survey entrance . Exclusion criterion : PD patient past history suicidal attempt , suicidal ideation tendency PD patient suicidal ideation PD patient past history suicidal tendency</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>